Department of Cardiology, The First Hospital of China Medical University, Shenyang, China.
Diabetes Metab Res Rev. 2024 Nov;40(8):e70004. doi: 10.1002/dmrr.70004.
To investigate the role of glucagon-like peptide 1 (GLP-1) in myocardial perfusion, focusing on its effects on coronary microcirculation and cardiovascular outcomes.
Review of foundational research and large-scale clinical trials, including Cardiovascular Outcome Trials (CVOTs), examining the cardiovascular effects of GLP-1. Systematic analysis of trial data to assess the impact of GLP-1 therapy on myocardial infarction, composite cardiovascular events, and stroke incidence.
GLP-1 therapy was found to significantly reduce myocardial infarction and composite cardiovascular events. Additionally, GLP-1 receptor agonists were observed to reduce stroke incidence, suggesting systemic effects on panvascular diseases. While direct protective effects on coronary microvasculature have been less studied, growing evidence supports GLP-1's role in comprehensive myocardial perfusion.
GLP-1 is a promising therapeutic agent for improving myocardial perfusion and reducing cardiovascular events. Its protection is likely associated with comprehensive improvements in myocardial perfusion, including effects on coronary microcirculation. Further research is needed to fully elucidate its mechanisms of action and potential clinical applications.
研究胰高血糖素样肽 1（GLP-1）在心肌灌注中的作用，重点关注其对冠状动脉微循环和心血管结局的影响。
回顾基础研究和大型临床试验，包括心血管结局试验（CVOT），以评估 GLP-1 对心血管的影响。系统分析试验数据，评估 GLP-1 治疗对心肌梗死、复合心血管事件和卒中发生率的影响。
GLP-1 治疗显著降低了心肌梗死和复合心血管事件的发生。此外，GLP-1 受体激动剂观察到卒中发生率降低，表明对泛血管疾病的系统影响。虽然对冠状动脉微循环的直接保护作用研究较少，但越来越多的证据支持 GLP-1 在全面心肌灌注中的作用。
GLP-1 是改善心肌灌注和减少心血管事件的有前途的治疗药物。其保护作用可能与全面改善心肌灌注有关，包括对冠状动脉微循环的影响。需要进一步研究以充分阐明其作用机制和潜在的临床应用。
Zotero 插件